- Home
- CEV vs IVVD Comparison
CEV vs IVVD Comparison
Compare CEV & IVVD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CEV
- IVVD
- Stock Information
- Founded
- CEV 1999
- IVVD 2020
- Country
- CEV United States
- IVVD United States
- Employees
- CEV N/A
- IVVD N/A
- Industry
- CEV Finance/Investors Services
- IVVD Biotechnology: Pharmaceutical Preparations
- Sector
- CEV Finance
- IVVD Health Care
- Exchange
- CEV Nasdaq
- IVVD Nasdaq
- Market Cap
- CEV 66.8M
- IVVD 63.4M
- IPO Year
- CEV N/A
- IVVD 2021
- Fundamental
- Price
- CEV $9.91
- IVVD $1.43
- Analyst Decision
- CEV
- IVVD Strong Buy
- Analyst Count
- CEV 0
- IVVD 4
- Target Price
- CEV N/A
- IVVD $3.64
- AVG Volume (30 Days)
- CEV 19.6K
- IVVD 15.0M
- Earning Date
- CEV 01-01-0001
- IVVD 11-13-2025
- Dividend Yield
- CEV 4.23%
- IVVD N/A
- EPS Growth
- CEV N/A
- IVVD N/A
- EPS
- CEV 0.36
- IVVD N/A
- Revenue
- CEV N/A
- IVVD $46,210,000.00
- Revenue This Year
- CEV N/A
- IVVD $385.94
- Revenue Next Year
- CEV N/A
- IVVD $62.62
- P/E Ratio
- CEV $29.36
- IVVD N/A
- Revenue Growth
- CEV N/A
- IVVD 1941.08
- 52 Week Low
- CEV $8.83
- IVVD $0.35
- 52 Week High
- CEV $10.91
- IVVD $2.74
- Technical
- Relative Strength Index (RSI)
- CEV 74.13
- IVVD 72.86
- Support Level
- CEV $9.45
- IVVD $0.96
- Resistance Level
- CEV $10.01
- IVVD $1.45
- Average True Range (ATR)
- CEV 0.06
- IVVD 0.19
- MACD
- CEV 0.05
- IVVD 0.05
- Stochastic Oscillator
- CEV 81.58
- IVVD 97.86
About CEV Eaton Vance California Municipal Income Trust Shares of Beneficial Interest
Eaton Vance CA Muni Income Trust is a non-diversified closed-end investment company. The company's investment objective is to provide current income exempt from regular federal income tax and California state personal income taxes. It invests in municipal obligations, issued by the State of California or its political subdivisions, agencies, authorities and instrumentalities and also has some exposure to corporate bonds.
About IVVD Invivyd Inc.
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.